Advertisement

Topics

Two cancer drug prices have already been hiked by 8% this year

03:13 EDT 4 Jul 2017 | Topix

Both Blincyto and Treanda are leukemia drugs, while Treanda is also approved for non-Hodgkin lymphoma. The recent increases follow a mid-January price hike for Blincyto and a Jan. 1 price increase for Treanda.

Original Article: Two cancer drug prices have already been hiked by 8% this year

NEXT ARTICLE

More From BioPortfolio on "Two cancer drug prices have already been hiked by 8% this year"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Leukemia
Leukemia is a type of cancer of the blood or bone marrow characterized by an abnormal increase of immature white blood cells called "blasts". Leukemia is a broad term covering a spectrum of diseases. In turn, it is part of the even broader grou...

Hodgkin lymphoma
Hodgkin Lymphoma is a  disorder caused by malignant proliferation of lymphocytes, which contain characteristic mirror-image nuclei (Reed-Sternburg cells). The resulting lymphadenopathy can be limited to a single lymph node region (Stage 1) or spread...